作者
Soo-Yon Rhee, Jose Luis Blanco, Michael R Jordan, Jonathan Taylor, Philippe Lemey, Vici Varghese, Raph L Hamers, Silvia Bertagnolio, Tobias F Rinke de Wit, Avelin F Aghokeng, Jan Albert, Radko Avi, Santiago Avila-Rios, Pascal O Bessong, James I Brooks, Charles AB Boucher, Zabrina L Brumme, Michael P Busch, Hermann Bussmann, Marie-Laure Chaix, Bum Sik Chin, Toni T D’Aquin, Cillian F De Gascun, Anne Derache, Diane Descamps, Alaka K Deshpande, Cyrille F Djoko, Susan H Eshleman, Herve Fleury, Pierre Frange, Seiichiro Fujisaki, P Richard Harrigan, Junko Hattori, Africa Holguin, Gillian M Hunt, Hiroshi Ichimura, Pontiano Kaleebu, David Katzenstein, Sasisopin Kiertiburanakul, Jerome H Kim, Sung Soon Kim, Yanpeng Li, Irja Lutsar, Lynn Morris, Nicaise Ndembi, Kee Peng Ng, Ramesh S Paranjape, Martine Peeters, Mario Poljak, Matt A Price, Manon L Ragonnet-Cronin, Gustavo Reyes-Terán, Morgane Rolland, Sunee Sirivichayakul, Davey M Smith, Marcelo A Soares, Vincent V Soriano, Deogratius Ssemwanga, Maja Stanojevic, Mariane A Stefani, Wataru Sugiura, Somnuek Sungkanuparph, Amilcar Tanuri, Kok Keng Tee, Hong-Ha M Truong, David AMC van de Vijver, Nicole Vidal, Chunfu Yang, Rongge Yang, Gonzalo Yebra, John PA Ioannidis, Anne-Mieke Vandamme, Robert W Shafer
发表日期
2015/4/7
期刊
PLoS medicine
卷号
12
期号
4
页码范围
e1001810
出版商
Public Library of Science
简介
Background
Regional and subtype-specific mutational patterns of HIV-1 transmitted drug resistance (TDR) are essential for informing first-line antiretroviral (ARV) therapy guidelines and designing diagnostic assays for use in regions where standard genotypic resistance testing is not affordable. We sought to understand the molecular epidemiology of TDR and to identify the HIV-1 drug-resistance mutations responsible for TDR in different regions and virus subtypes.
Methods and Findings
We reviewed all GenBank submissions of HIV-1 reverse transcriptase sequences with or without protease and identified 287 studies published between March 1, 2000, and December 31, 2013, with more than 25 recently or chronically infected ARV-naïve individuals. These studies comprised 50,870 individuals from 111 countries. Each set of study sequences was analyzed for phylogenetic clustering and the presence of 93 surveillance drug-resistance mutations (SDRMs). The median overall TDR prevalence in sub-Saharan Africa (SSA), south/southeast Asia (SSEA), upper-income Asian countries, Latin America/Caribbean, Europe, and North America was 2.8%, 2.9%, 5.6%, 7.6%, 9.4%, and 11.5%, respectively. In SSA, there was a yearly 1.09-fold (95% CI: 1.05–1.14) increase in odds of TDR since national ARV scale-up attributable to an increase in non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance. The odds of NNRTI-associated TDR also increased in Latin America/Caribbean (odds ratio [OR] = 1.16; 95% CI: 1.06–1.25), North America (OR = 1.19; 95% CI: 1.12–1.26), Europe (OR = 1.07; 95% CI: 1.01–1.13), and upper-income Asian …
学术搜索中的文章
SY Rhee, JL Blanco, MR Jordan, J Taylor, P Lemey… - PLoS medicine, 2015